Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
287.8 USD | -0.14% | +6.73% | -8.82% |
04/06 | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
03/06 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
Sales 2024 * | 19.8B 2.89B 241B | Sales 2025 * | 23.62B 3.44B 288B | Capitalization | 124B 18.16B 1,516B |
---|---|---|---|---|---|
Net income 2024 * | 4.68B 683M 57B | Net income 2025 * | 6.61B 964M 80.53B | EV / Sales 2024 * | 4.98 x |
Net cash position 2024 * | 25.92B 3.78B 316B | Net cash position 2025 * | 32.36B 4.72B 394B | EV / Sales 2025 * | 3.9 x |
P/E ratio 2024 * |
28.4
x | P/E ratio 2025 * |
20.5
x | Employees | 2,286 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Genmab A/S
1 day | -0.14% | ||
1 week | +6.73% | ||
Current month | +4.42% | ||
1 month | -0.66% | ||
3 months | -0.74% | ||
6 months | -8.47% | ||
Current year | -8.82% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 01/99/01 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01/07/01 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23/20/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01/17/01 |
Director/Board Member | 73 | 01/03/01 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 01/16/01 |
Date | Price | Change | Volume |
---|---|---|---|
04/24/04 | 287.8 | -0.14% | 387 |
03/24/03 | 288.2 | +4.56% | 403 |
31/24/31 | 275.7 | -3.03% | 443 |
30/24/30 | 284.3 | +3.58% | 423 |
29/24/29 | 274.5 | -5.34% | 254 |
Delayed Quote OTC Markets, June 05, 2024 at 01:24 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B | |
+83.67% | 9.02B |
- Stock Market
- Equities
- GMAB Stock
- GNMSF Stock